RE:RE:RE:New Press Release - Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal HealthI would rather like to see them selling the right to use their tech in any animal products for a good chunk of money. Because they will need more than 6-11M to clear the debt and run the business for several months since revyve will take some time to be profitable.
francoisl13 wrote: One thing I forgot to mention is my previous posts is that it will be interesting to know if KNE keeps the patents/IP related to the animal health biofilm applications and ultimately gets some license fees from the STEM buyer and their potential clients.
I hope this will be clarified when they make the sales annoucements.